Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T, Hagihara M, Sahara N, Tamai Y, Ishii R, Tamaki S, Wake A, Tajika K, Sakai R, Kobayashi T, Hua J, Inoue M, Aisa Y, Fujisawa S, Miyazaki K, Irie S, Tanaka E, Higashihara M.
Nakazato T, et al. Among authors: tamai y.
Ann Hematol. 2021 Nov;100(11):2745-2754. doi: 10.1007/s00277-021-04592-y. Epub 2021 Jul 31.
Ann Hematol. 2021.
PMID: 34333665
Clinical Trial.